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Abstract 
Cereblon (CRBN), a substrate receptor for Cullin-ring E3 ubiquitin ligase (CRL), is a major 
target protein of immunomodulatory drugs. An earlier study demonstrated that CRBN directly 
interacts with the catalytic  subunit of AMP-activated protein kinase (AMPK), a master regulator of 
energy homeostasis, down-regulating the enzymatic activity of AMPK. However, it is not clear how 
CRBN modulates AMPK activity. To investigate the mechanism of CRBN-dependent AMPK 
inhibition, we measured protein levels of each AMPK subunit in brains, livers, lungs, hearts, spleens, 
skeletal muscles, testes, kidneys, and embryonic fibroblasts from wild-type and Crbn
-/-
 mice. Protein 
levels and stability of the regulatory AMPK subunit were increased in Crbn-/- mice. Increased 
stability of AMPK in Crbn-/- MEFs was dramatically reduced by exogenous expression of Crbn. In 
wild-type MEFs, the proteasomal inhibitor MG132 blocked degradation of AMPK. We also found 
that CRL4
CRBN
 directly ubiquitinated AMPK. Taken together, these findings suggest that CRL4CRBN 
regulates AMPK through ubiquitin-dependent proteasomal degradation of AMPK. 
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1. Introduction 
Cereblon (CRBN), initially identified as a target gene of human intellectual disability [1], is 
a substrate receptor for the Cullin-4A/B RING E3 ubiquitin ligase (CRL4A) comprising Cullin-4A/B, 
Damage-specific DNA-binding protein 1 (DDB1), and RING-box protein 1 (ROC1) [2, 3]. 
CRL4A
CRBN
 mediates the ubiquitination and proteasomal degradation of endogenous substrates such 
as Ca
2+
- and voltage-activated K
+
 (BK) channels [4, 5], Meis homeobox 2 (MEIS2) [6], CLC-1 
chloride [7, 8], and glutamine synthetase (GS) [9]. CRBN was also reported as a primary target 
protein of immunomodulatory drugs, including thalidomide [3] and its derivatives lenalidomide and 
pomalidomide [10]. Thalidomide was originally prescribed as a sedative for pregnant women to 
prevent morning sickness and found to be a teratogen, but thalidomide and its derivatives are now 
widely used in the treatment of hematologic malignancies such as multiple myeloma [11, 12] and 5q 
deletion-associated myelodysplastic syndrome [13]. Thalidomide binds CRBN and inhibits CRL4
CRBN
 
activity, leading to a teratogenic effect on fetal development [3]. Immunomodulatory drugs bind to 
CRBN and change its substrate specificity, promoting recruitment of neosubstrates, including Ikaros 
(IKZF1), Aiolos (IKZF3) [14, 15], and Casein kinase 1A1 (CK1a) [16], leading to their ubiquitin-
dependent degradation. Degradation of IKZF1 and IKZF3, which are essential transcription factors in 
multiple myeloma, results in the death of malignant cells. 
AMPK is a master metabolic sensor and regulator of energy homeostasis [17]. AMPK is a 
heteromeric complex composed of a catalytic  subunit and two regulatory  and  subunits [18]. The 
catalytic  subunits contain conventional serine/threonine kinase domains, which are phosphorylated 
by upstream kinases such as liver kinase B1 (LKB1) [19]. The  subunit contains a carbohydrate-
binding module, which allows AMPK to associate with glycogen. The carboxy-terminal domain of the 
 subunit interacts with both the  and  subunits, serving as a scaffolding protein. The  subunit 
includes four tandem repeats of the Cystathionine -synthase domain, which are involved in binding 
adenine nucleotides [20, 21]. Binding of AMP or ADP to the  subunit leads to a conformational 
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change that promotes phosphorylation of the  subunit at Thr172 by upstream kinases, as well as 
protection against dephosphorylation [22, 23 24]. When activated, AMPK phosphorylates various 
downstream substrates, promoting deactivation of ATP-consuming anabolic pathways and activation 
of ATP-generating catabolic pathways [25, 26]. 
Previously, we identified that CRBN inhibits AMPK activity through direct binding to its  
subunit in vitro and in vivo, and that CRBN binding reduces the content of the  subunit specifically in 
the AMPK complex [27, 28]. However, the molecular mechanism of CRBN-dependent reduction of 
AMPK is not fully understood. In the present study, we identified that the content of AMPK in the 
AMPK complex was decreased by exogenous CRBN. The amount of endogenous AMPK and its 
stability were increased in Crbn
-/-
 mice. Further, we demonstrated that CRL4
CRBN
-dependent 
ubiquitination can modulate  subunit content in the AMPK complex. Taken together, our results 
demonstrate that CRBN inhibition of AMPK activity is due to ubiquitin-dependent degradation of 
AMPK following interaction between CRBN and AMPK. 
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2. Materials and methods 
2.1 Experimental animals 
Male wild-type C57BL/6J and Crbn
-/-
 mice [28] were used in this study. Animals were 
maintained under specific pathogen-free conditions. All experiments were approved by the Animal 
Care and Use Committee of Gwangju Institute of Science and Technology. 
 
2.2. Plasmid construction and transfection 
Rat AMPK was inserted into the pFlag-CMV vector (Flag-Ampk). Generation of plasmid 
encoding HA-tagged rat Crbn (HA-Crbn) was described previously [27]. Cells were transfected using 
either Lipofectamine 2000 (Invitrogen) or FuGENE HD (Promega) according to the manufacturer’s 
protocols.  
 
2.3. Cell culture 
Mouse embryonic fibroblasts (MEFs), Crbn knockdown H1299 cells, and Crbn
-/-
 HEK293T 
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Hyclone) with 10% (v/v) fetal 
bovine serum (FBS, Hyclone). Wild-type and Crbn
-/-
 MEFs were isolated from E14.5 embryos born to 
heterozygous intercrosses and assayed at passages 3–6, as previously described [29].  
 
2.4. Quantitative real-time PCR analysis. 
Total RNA was isolated from wild-type and Crbn
-/-
 MEFs by TRIzol reagent (Invitrogen), 
according to the manufacturer’s protocol. Complementary DNA (cDNA) was synthesized using 
CycleScript RT PreMix (Bioneer). mRNA levels were measured using TB Green
TM
 Premix Ex Taq
TM
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(TaKaRa) and Thermal Cycler Dice Real Time System. The following primers were used for 
amplification. Crbn, forward: 5’ AGC ATG GTG CGG AAC TTA ATC-3’, and reverse: 5’-ATC TCT 
GCT GTT GTC CCA AAC-3’; Ampk1, forward: 5’-GTC GAC GTA GCT CCA AGA CC-3’, and 
reverse: 5’-ATC GTT TTC CAG TCC CTG TG-3’; Ampk1, forward: 5’-GTT GCT GTT GCT TGT 
TCC AA-3’, and reverse: 5’-ATA CTG TGC CTG CCT CTG CT-3’; Ampk1, forward: 5’-TCC CTA 
GAC CTC ACC ACA CC-3’, and reverse: 5’-GTC TGC ACA GCA CAA GAA CC-3’; 18s rRNA, 
forward: 5’-GTA ACC CGT TGA ACC CCA TT-3’, and reverse: 5’-CCA TCC AAT CGG TAG TAG 
CG-3’. Expression was normalized to 18s rRNA levels. 
 
2.5. Tissue lysate preparation 
Brains, livers, lungs, hearts, spleens, skeletal muscles, testes, and kidneys were isolated from 
8-week-old mice. Tissues were homogenized in ice-chilled buffer (20 mM Tris-HCL, pH 7.4, 0.32 M 
sucrose, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 10 g/ml aprotinin, 15 g/ml leupeptin, 50 mM 
NAF, and 1 mM sodium orthovanadate). 
 
2.6. Western blot analysis 
Proteins were separated by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) 
membranes. After blocking with 3% BSA in TBS-T (137 mM NaCl, 20 mM Tris-Cl, pH 7.6, 0.1% 
Tween 20), membranes were incubated with various primary antibodies, including rabbit polyclonal 
anti-CRBN (Sigma), mouse monoclonal anti-AMPK (Invitrogen), rabbit polyclonal anti-AMPK 
(Cell Signaling), rabbit polyclonal anti-AMPK1 (Abcam), rabbit polyclonal anti--actin (Sigma), 
rabbit polyclonal anti-GAPDH (Abfrontier), monoclonal anti-HA (Cell Signaling), monoclonal anti-
-tubulin (Sigma), rabbit polyclonal anti-GFP (Abcam), and monoclonal anti-Flag (Sigma). The blots 
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were then incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit or mouse secondary 
antibody (Jackson ImmunoResearch), and developed using enhanced chemiluminescence detection 
(ECL; Amersham Pharmacia). 
 
2.7. Cycloheximide and MG132 chase experiments 
Wild-type and Crbn
-/-
 MEFs were seeded overnight in six-well plates, and then treated with 
25 g/ml cycloheximide (ChX; Sigma) or MG132 (Calbiochem) for the indicated times. Treated cells 
were harvested for Western blot analysis.  
 
2.8. In vivo ubiquitination 
H1299 cells stably expressing control shRNA or Crbn shRNA were transiently transfected 
with Flag-Ampk and HA-Ub for 30 hr, and then treated with MG132 (10 M) for 3 hr. Cells were 
then lysed using 0.3 ml denaturing IP lysis buffer (1% SDS, 50 mM Tris-HCL, 10 mM DTT, pH 7.5) 
and boiled for 5 minutes. Denatured proteins were diluted in immunoprecipitation buffer (10 mM 
Tris-HCl, 150 mM NaCl, 0.5% NP-40, pH 7.6) and immunoprecipitated with anti-Flag resin. 
Immunoprecipitated proteins were measured by Western blot analysis. 
 
2.9. In vitro ubiquitination 
An in vitro ubiquitination assay was performed as described previously [30, 31]. Briefly, 
HEK293T cells were transiently transfected with Flag-Ampk or empty vector. After 30 hr of 
transfection, cells were treated with Bortezomib (1M) for 6 hr. Cell were then lysed in IP buffer and 
immunoprecipitated with Flag M2 agarose beads for 3 hr. After washing with IP buffer and 
ubiquitination buffer (50 mM Tris-HCl, pH 8.0, 10 mM MgCl2, 0.2 mM CaCl2, 1 mM DTT, 100 nM 
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MG132), the beads were incubated at 30C for 1 hr in 30 l ubiquitination buffer containing E1 (0.5 
M), UbcH5a (0.5 M), UbcH3 (1.67 M), ubiquitin (60 M), ATP (4 mM), recombinant CUL4A-
RBX1, and DDB1-CRBN (250 M) purified from insect cells. The samples were subjected to 
Western blot analysis. 
 
2.10. Statistical analysis 
All displayed values represent means  SEM. Significant differences between groups were 
determined using two-tailed unpaired Student’s t-test, and multiple comparisons were performed 
using one-way ANOVA. Differences with p < 0.05 were considered statistically significant, and are 
indicated in the figure legends.   
 
3. Results 
3.1. Protein levels of AMPK were specifically increased in Crbn-/- mice 
To investigate the regulatory mechanism of AMPK activity by CRBN, we first analyzed 
endogenous protein levels of AMPK subunits in wild-type and Crbn
-/-
 MEFs. AMPK protein levels 
were higher in Crbn
-/-
 MEFs than in the wild type (Fig 1A-D). Next, we examined the endogenous 
protein levels of AMPK ,  and  subunits in various tissues of Crbn-/- mice. Protein levels of 
AMPK, but not AMPK or AMPK, were increased in the kidney, heart, liver spleen and skeletal 
muscle of Crbn
-/-
 mice (Fig 1E). We then compared the mRNA levels of each AMPK subunit in wild-
type and Crbn
-/-
 MEFs. No significant differences were observed in the mRNA expression levels of 
each subunit (Fig 1F-I). These results suggest that CRBN-dependent reduction of AMPK was likely 
post-translational. 
 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
9 
 
3.2. CRBN promoted AMPKdegradation. 
We then evaluated the effect of CRBN on stability of the AMPK ,  and subunits. To 
determine if the degradation rate of each AMPK subunit was altered by Crbn deletion, we treated 
wild-type and Crbn
-/-
 MEFs with cycloheximide (ChX), a protein synthesis inhibitor. MEFs were 
harvested at different time points (0, 1, 3, 6, and 9 hr) after ChX treatment, and protein levels were 
measured using Western blot analysis (Fig 2A). No significant differences in protein levels of 
AMPK or AMPK were detected between cells treated with ChX at all time points tested (Fig 2B 
and 2D). Contrastingly, protein levels of AMPK were increased significantly at the initial time point 
of ChX treatment, and degraded much more slowly in Crbn
-/-
 MEFs relative to wild-type (Fig 2E). 
While AMPK protein level decreased steadily in wild-type MEFs, AMPK remained stable up to 9 hr 
after the initial reduction in Crbn
-/-
 MEFs (Fig 2E). The amount of phosphorylated (P-) AMPK was 
higher in Crbn
-/-
 compared with wild-type at all time-points tested (Fig 2C). Moreover, we compared 
the mRNA levels of each AMPK subunits in wild-type and Crbn
-/-
 MEFs. No significant differences 
were observed in the mRNA expression levels of each subunit (Fig 2G-I). 
To confirm the degradation rate of AMPK subunits by Crbn deletion, the effect of Crbn 
knockdown using TD-165, a well characterized CRBN degrader [32], on stability of AMPK subunits 
was also examined (Fig 3A). Protein levels of AMPK and AMPK were decreased at similar rates in 
DMSO-treated and TD-165-treated wild-type MEFs (Fig 3B and 3D), while protein levels of AMPK 
were decreased much more slowly in TD-165-treated relative to DMSO-treated wild-type MEFs (Fig 
3E). 
To investigate the effect of exogenous CRBN on the stability of AMPK subunits, we 
transiently transfected Crbn
-/-
 MEFs with HA-Crbn or control plasmid. One day after transfection, we 
treated the cells with ChX and measured protein levels of AMPK subunits by Western blot analysis at 
various time points (Fig 4A). In the absence of exogenous CRBN, AMPK was relatively stable, with 
more than 50% of AMPK remaining after 9 hr ChX treatment. However, AMPK was dramatically 
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decreased by ectopic expression of Crbn, with a half-life of less than 3 hr (Fig 4E). Protein levels of 
P-AMPK were lower in the presence of exogenous CRBN (Fig 4C). However, there was no difference 
in the mRNA levels of AMPK subunits between the groups (Fig 4F-H). Exogenous CRBN did not 
affect the degradation rates of AMPK or AMPK (Fig 4B and 4D). These results indicated that 
CRBN accelerated the degradation of AMPK, but not AMPK or AMPK. 
 
3.3 CRBN regulated AMPK in a proteasome-dependent manner. 
Because CRBN functions as the substrate receptor of CRL4 E3 ubiquitin ligase and recruits 
specific target proteins for degradation through the ubiquitin proteas me pathway, we surmised that 
CRBN reduction of AMPK protein level could be due to proteasomal degradation. We assessed the 
accumulation rates of AMPK subunits in wild-type and Crbn
-/-
 MEFs. Cells were treated with MG132 
for 0, 1, 3, 6, and 9 hr to inhibit proteasome activity. We than examined protein levels of AMPK,  
and  by Western blot analysis (Fig 5A). AMPK and AMPK accumulated at similar rates in wild-
type and Crbn
-/-
 MEFs (Fig. 5B and D), while AMPK accumulated at a much faster rate in wild-type 
MEFs (Fig. 5E). After a 9 hr treatment with MG132, AMPK, which was initially lower in wild-type 
MEFs relative to Crbn
-/-
 MEFs, increased to similar levels as that of Crbn
-/-
 MEFs (Fig 5E). P-
AMPKaccumulated more rapidly in wild-type MEFs (Fig 5C). There were no statistical differences 
in the mRNA expression levels of each AMPK subunit between cells (Fig 5G-I). MG132 preservation 
of AMPK against CRBN-dependent degradation strongly suggested that CRBN degradation of 
AMPK was modulated by the ubiquitin proteasome. 
 
3.4. Ubiquitination of AMPK was mediated by CRL4CRBN. 
Because Crbn knockout increased AMPK protein stability without affecting mRNA levels, 
we further investigated whether AMPK was a substrate of CRBN. To determine whether AMPK 
was ubiquitinated by CRL4
CRBN
, we co-expressed Flag-tagged AMPK (Flag-Ampk) and HA-tagged 
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ubiquitin (HA-Ub) in H1299 cells stably expressing control or Crbn shRNA. After 30 hr of 
transfection, cells were treated with MG132 to stabilize ubiquitinated proteins, and Flag-AMPK was 
immunoprecipitated. Subsequent Western blot analysis with HA antibodies to detect ubiquitinated 
proteins revealed a high-molecular weight smear of Flag-AMPK. In addition, Crbn knockdown 
decreased AMPK ubiquitination (Fig 6A).  
Next, we performed an in vitro ubiquitination assay to investigate whether CRL4
CRBN
 
directly ubiquitinated AMPK. We purified Flag-tagged AMPK, CUL4A-RBX1, and DDB1-CRBN. 
The reactions were analyzed by Western blotting using anti-Flag antibody to detect a high-molecular 
weight smear of Flag-AMPK. In vitro ubiquitination of Flag-AMPK was markedly increased after 
supplemental addition of E1, E2, ubiquitin, and CRL4
CRBN
, and was inhibited by methylated ubiquitin 
(Me-Ub) (Fig 6B). Taken together, these results suggest that CRL4
CRBN
 promoted AMPK 
ubiquitination.  
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4. Conclusions 
AMPK, which consists of a catalytic  subunit and regulatory  and  subunits, is a highly 
conserved master regulator of metabolism, the activity of which is regulated by cellular AMP/ATP 
and ADP/ATP ratios [17, 18]. Among the AMPK subunits, the regulatory  subunits contain four 
tandem repeats of CBS domains responsible for adenine nucleotide binding (AMP, ADP, or ATP), 
allowing AMPK to sense cellular energy status [20, 21, 22, 23]. Further, several mutations in the  
subunit lead to changes in AMPK activity and sensitivity to AMP [33, 34]. 
Previously, we reported that CRBN negatively modulates AMPK activity via direct binding 
to AMPK, and that this binding decreases the level of AMPKin the AMPK complex [27]. 
Subsequently, we demonstrated that AMPK activity was constitutively activated in Crbn knockout 
mice under normal conditions and that Crbn knockout mice fed a long-term high-fat diet (HFD) 
showed a noticeable improvement in their metabolic status [28]. In the present study, we focused on 
the molecular mechanism of CRBN-mediated AMPK inhibition, and demonstrated that ubiquitin-
dependent proteasomal degradation of AMPK by CRL4CRBN suppressed AMPK. 
First, we measured the endogenous protein levels of AMPK subunits in the absence and 
presence of the Crbn gene (Fig. 1). In Crbn
-/-
 MEFs, protein levels of endogenous  subunits, but not 
 or  subunits, were increased. Because no significant differences were observed in  subunit mRNA 
levels between wild-type and Crbn
-/-
 MEFs, the decreased protein level of AMPK was likely due to 
post-translational processes. We next compared AMPK subunit protein levels in various tissues from 
wild-type and Crbn
-/-
 mice, and observed similar increases of AMPK in several Crbn-/- tissues, most 
notably in the kidney, liver, heart, and spleen (Fig 1E). The tissue-specific effects of Crbn knockout 
were not simply due to the abundance of CRBN in specific tissues per se, and thus tissue-specific 
CRBN modulation of AMPK is a topic of future investigation.  
Because CRBN recruits its target proteins for ubiquitination, we examined the protein 
stability of AMPK under inhibition of protein synthesis and imbibition of proteasomal degradation. 
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When de novo protein synthesis was blocked, AMPK was degraded more slowly in the absence of 
CRBN, while AMPK and AMPK were unaffected by CRBN (Fig 2 and 3). Further, 
AMPKdegradation was facilitated by the presence of exogenous CRBN (Fig 4). Furthermore, in the 
presence of a proteasomal inhibitor, only AMPK accumulated more rapidly in wild-type MEFs than 
in Crbn
-/-
 MEFs (Fig 5). Moreover, no significant differences in mRNA levels of AMPK subunits 
were observed between cells treated ChX or MG132 at all time points (Fig 2, 4 and 5). These results 
strongly suggested CRBN-dependent ubiquitination and subsequent degradation of AMPK via the 
ubiquitin-proteasome pathway. This was validated by an in vitro ubiquitination assay of AMPK (Fig 
6).  
Control of AMPK phosphorylation by upstream kinases and phosphatases is the most 
characterized mechanism of AMPK regulation. However, several recent studies identified that post-
translational modification of AMPK levels through ubiquitination also regulates AMPK activity [35]. 
AMPK is ubiquitinated by UBE2O, an E2 ubiquitin-conjugating enzyme, and subsequently targeted 
for proteasomal degradation [36]. Tripartite motif-containing 28 (TRIM28) [37] and Makorin ring 
finger protein 1 (MKRN1), an E3 ubiquitin ligase [38], also regulate AMPK ubiquitination and 
proteasomal degradation. In brown adipose tissue, Cell death-inducing DFFA-like effector a (Cidea) 
ubiquitinates and degrades AMPK [39]. However, this is the first report to identify ubiquitination of 
the AMPK subunit.  
The experimental results of this study, together with previous findings [27, 28], suggest that 
CRBN may interact with the subunit of AMPK as a trimeric complex, and that CRL4CRBN may 
transfer ubiquitin to specific site(s) in the subunit for subsequent proteasomal degradation. Thus, the 
present study identifies a novel mechanism for regulation of AMPK activity through CRL4
CRBN
-
dependent degradation of AMPK, and provides a plausible explanation for the HFD-induced 
metabolic disorder-resistant phenotype observed in Crbn
-/-
 mice [28]. 
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Figure 1: Protein and mRNA levels of AMPK subunits in wild-type and Crbn
-/-
 MEFs and 
somatic tissues. 
(A) Wild-type and Crbn
-/-
 MEF lysates were subjected to Western blot analysis with the indicated 
antibodies. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control, and 
ratios of (B) AMPK, (C) AMPK, and (D) AMPK to GAPDH were calculated. (E) Proteins 
extracted from various tissues (brain, liver, lung, heart, spleen, skeletal muscle, testis, and kidney) of 
wild-type and Crbn
-/-
 mice were separated by SDS-PAGE and immunoblotted with anti-AMPK, 
anti-AMPK, anti-AMPK, and anti--actin antibodies. Eight-week-old male mice were used. (F-I) 
Total RNA was isolated from wild-type and Crbn
-/-
 MEFs, and subjected to quantitative real-time 
PCR analysis to determine the expression of (F) Crbn, (G) Ampk, (H) Ampk, and (I) Ampk. 
Expression was normalized against 18s rRNA levels. # and ## indicate AMPK isoform 1 and 2, 
respectively. Error bars represent the SEM (n=6). *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001. 
 
Figure 2: Increased stability of AMPK in Crbn-/- MEFs. 
Wild-type and Crbn
-/-
 MEFs were treated with ChX (25 g/ml) for the specified times. Cell lysates 
were analyzed by Western blot. (A) Representative Western blots of endogenous AMPK, P- 
AMPKAMPK, AMPK1, CRBN, and -tubulin. -Tubulin was used as a loading control. (B-F) 
Western blotting results in (A) were quantified by densitometry and values were plotted. Relative 
mRNA levels of (G) Ampk, (H) Ampk, and (I) Ampk. Expression was normalized against 18s 
rRNA levels. A single-exponential decay curve was fit. Error bars represent the SEM (n=4). Empty 
circles indicate individual values of protein or mRNA level. Filled circles indicate mean values of 
protein or mRNA level. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001 vs. wild-type MEFs 
untreated with ChX. †P < 0.05, ††P < 0.01, †††P < 0.005, ††††P < 0.001 vs. Crbn-/- MEFs untreated 
with ChX. §P < 0.05, §§P < 0.01, §§§P < 0.005, §§§§P < 0.001 vs. wild-type MEFs at the same ChX 
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treatment time point. 
 
Figure 3: Increased stability of AMPK by CRBN knockdown 
Wild-type MEFs were treated with TD-165 (0.5 M). After 24 hr, cells were treated with ChX (25 
ug/ml) for the indicated times. Cell lysates were analyzed by Western blot. (A) Representative 
Western blots of endogenous AMPK, P-AMPK, AMPK, AMPK1, CRBN, and -tubulin. -
Tubulin was used as a loading control. (B-F) Western blotting results in (A) were quantified by 
densitometry and values were plotted. # indicate CRBN.  A single-exponential decay curve was fit. 
Error bars represent the SEM (n=4). Empty circles indicate individual values of protein level. Filled 
circles indicate mean values of protein levels. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001 vs. 
wild-type MEFs untreated with ChX. †P < 0.05, ††P < 0.01, †††P < 0.005, ††††P < 0.001 vs. Crbn-/- 
MEFs untreated with ChX. §P < 0.05, §§P < 0.01, §§§P < 0.005, §§§§P < 0.001 vs. wild-type MEFs 
at the same ChX treatment time point. 
 
Figure 4: Exogenous CRBN accelerated AMPK degradation. 
Crbn
-/-
 MEFs were transiently transfected with pcDna3-HA or pcDna3-HA/Crbn (HA-Crbn). After 24 
hr, cells were treated with ChX (25 g/ml) for the indicated times. (A) Cell lysates were subjected to 
Western blot analysis for AMPK, P-AMPK, AMPK, AMPK1, -tubulin, HA, and GFP. GFP was 
used as a marker for transfection efficiency and -tubulin was used as a loading control. (B-E) The 
results in (A) were quantified and normalized against -tubulin levels, and values were plotted. 
Relative mRNA levels of (F) Ampk, (G) Ampk, and (H) Ampk. Expression was normalized against 
18s rRNA levels. A single-exponential decay curve was fit. Error bars represent the SEM (n=4). 
Empty circles indicate individual values of protein or mRNA level. Filled circles indicate mean values 
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of protein or mRNA levels. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001 vs. wild-type MEFs 
untreated with ChX. †P < 0.05, ††P < 0.01, †††P < 0.005, ††††P < 0.001 vs. Crbn-/- MEFs untreated 
with ChX. §P < 0.05, §§P < 0.01, §§§P < 0.005, §§§§P < 0.001 vs. wild-type MEFs at the same ChX 
treatment time point. 
 
Figure 5: Proteasomal inhibition prevented CRBN-mediated AMPK degradation.  
Wild-type and Crbn
-/-
 MEFs were treated with MG132 (0.5 M) for the indicated times. Cell lysates 
were analyzed by Western blot. (A) Representative Western blots of endogenous AMPK, P-
AMPKAMPK, AMPK1, CRBN, and -tubulin. -Tubulin was used as a loading control. (B-F) 
The results in (A) were quantified by densitometry and normalized to -tubulin, and values were 
plotted. Relative mRNA levels of (G) Ampk, (H) Ampk, and (I) Ampk. Expression was normalized 
against 18s rRNA levels. A single-exponential growth curve was fitted. Error bars represent the SEM 
(n=4). Empty circles indicate individual values of protein or mRNA level. Filled circles indicate mean 
values of protein or mRNA levels. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001 vs. wild-type 
MEFs untreated with MG132. †P < 0.05, ††P < 0.01, †††P < 0.005, ††††P < 0.001 vs. Crbn-/- MEFs 
untreated with MG132. §P < 0.05, §§P < 0.01, §§§P < 0.005, §§§§P < 0.001 vs. wild-type MEFs at 
the same MG132 treatment time point. 
 
Figure 6: CRL4
CRBN
 regulated AMPK ubiquitination. 
(A) H1299 cells stably expressing control (CT) or Crbn shRNA were transiently transfected with 
Flag-Ampk and HA-ubiquitin (Ub). After 30 hr of transfection, cells were treated with MG132 (10 M) 
for 3 hr. Cell lysates were immunoprecipitated with `anti-Flag resin under denaturing conditions. The 
input and immunoprecipitated fractions were detected by Western blotting for HA and Flag. LC 
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indicates the IgG light chain. Numerical band intensity (mean ± SEM) was measured by NIH image 
J and indicated figure. (B) Flag-AMPK was purified from Crbn-/- 293FT cells. An in vitro 
ubiquitination assay of Flag-AMPK was performed in the presence or absence of E1 + E2 and HA-
Ub. Where indicated, methylated Ub (Me-Ub) or recombinant CUL4A
CRBN
 purified from insect cells 
was added. (Ub)n indicates polyubiquitination. 
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Highlights 
 Ablation of the Crbn gene increased protein levels of the AMP-activation protein kinase 
(AMPK)  subunit. 
 Exogenous CRBN promoted degradation of AMPK. 
 Proteasomal inhibition attenuated CRBN-dependent AMPK degradation. 
 AMPK was ubiquitinated and degraded by CRL4CRBN. 
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